ATOS ATOSSA THERAPEUTICS, INC. Insider Trading

ATOS CEO QUAY purchases 11,239 shares at $0.88, increasing holdings 422.7%; company burns cash amid 99.7% revenue decline

CEO Steven C. Quay acquired 11,239 shares at $0.88, bringing his total position to 13,898 shares and raising his ownership by 422.7% from 2,659 shares. This is a substantial voluntary accumulation at a price far below the current $13.05 level and significantly below the 52-week high of $24.45. However, the company's recent financial state demands scrutiny: latest quarterly revenue is $0.00, annual revenue growth is -99.7%, and net income was -$6,718,000 in the most recent full fiscal year. The 30-day price surge of +31.1% and 90-day gain of +9.4% suggest recent upward momentum, but fundamental profitability and revenue remain absent. This purchase warrants deeper examination into the company's cash runway, path to revenue, and whether the CEO's acquisition reflects asymmetric information or is a routine equity stake alignment gesture.

Director Remmel H. Lawrence buys 10,000 shares of ATOS at $0.70, raising holdings 3891.1%; company posted $-7.2M net loss and -99.7% revenue decline

Remmel H. Lawrence, a Director, purchased 10,000 shares at $0.70 on 2025-03-26, increasing his stake from 257 shares to 10,257 shares—a 3891.1% increase in holdings. This substantial accumulation occurs against a backdrop of severe operational distress: the company reported zero revenue in the latest quarter, a net income loss of $-7.2M on a full-year basis, and an annual revenue decline of -99.7%, indicating the business has effectively collapsed operationally. The stock currently trades at $10.44, a 66.9% decline from its 52-week high of $31.50, and has fallen 9.5% over 30 days and 29.1% over 90 days. The purchase price of $0.70 represents a dramatic discount to the current market price, suggesting the director acquired these shares before a recent recovery or revaluation event. This pattern—a substantial insider purchase at a depressed historical entry point amid fundamental deterioration—warrants examination to determine whether the purchase reflects a disciplined conviction in a turnaround thesis or if other factors (such as scheduled or contingent equity agreements) are driving the transaction.